Glinkina L S, Bruvere R Zh, Venskus D R, Garklava R R, Muceniece A J
Vopr Onkol. 1992;38(5):540-7.
The effect of rigvir, an immunomodulator of the viral origin, on cell-mediated immunity was studied in patients with skin malignant melanoma. Rosette formation and monoclonal antibody techniques were used to measure blood immunocompetent cell levels in patients with the above pathology, cases of benign skin tumors and healthy subjects. Rigvir was shown to influence natural resistance by raising blood monocyte and large granule-containing lymphocyte levels. It potentiated recruitment of pre-T-lymphocytes and young active T-lymphocytes to the peripheral blood.
研究了病毒来源的免疫调节剂里格维（Rigvir）对皮肤恶性黑色素瘤患者细胞介导免疫的影响。采用玫瑰花结形成试验和单克隆抗体技术，对上述病理患者、良性皮肤肿瘤患者及健康受试者的血液免疫活性细胞水平进行了检测。结果显示，里格维可通过提高血液单核细胞和含大颗粒淋巴细胞水平来影响自然抵抗力。它还能增强前T淋巴细胞和年轻活性T淋巴细胞向外周血的募集。
